8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
2018 / Single-centre, open-label, fixed-sequence trial
Twelve healthy Chinese volunteers received a single 8 mg dose of blonanserin while fasting, with a high-fat meal, or with 250 mL of grapefruit juice across three periods with a 7-day washout. High-fat meals significantly increased blonanserin AUCt 2.58-fold (90% CI 2.21, 3.02) compared to fasting. Co-administration with grapefruit juice prolonged the elimination half-life of blonanserin from 9.7 to 21.4 hours and increased exposures to blonanserin and its metabolite by 5.82-fold (90% CI 4.57, 7.42) and 1.81-fold (90% CI 1.65, 1.98), respectively.
Shang DW, Wang ZZ, Hu HT, et al. Eur J Clin Pharmacol, 2018. PMID 28975417
1993 / Three-way crossover study
Twelve healthy volunteers on a controlled aluminium (Al) diet consumed a tea infusion (500 ml/70 kg body weight) with milk, with lemon juice, or mineral water across a three-way crossover design. Plasma Al concentrations were measured before and up to 24 hours after consumption. Intake of up to 1.60 mg Al from tea with milk or lemon juice did not raise plasma Al levels compared with drinking mineral water containing approximately 0.001 mg Al.
Drewitt PN, Butterworth KR, Springall CD, et al. Food Chem Toxicol, 1993. PMID 8444383
1993 / Intervention trial with in vitro microsomal component
Researchers evaluated the effects of grapefruit juice and naringenin on human CYP1A2 activity using caffeine as a probe substrate. In vitro, naringin competitively inhibited caffeine 3-demethylation by human liver microsomes (Ki = 7-29 microM). In vivo among 12 participants, grapefruit juice (1.2 l day-1 containing 0.5 g l-1 naringin) decreased oral caffeine clearance by 23% (95% CI: 7%-30%) and prolonged its half-life by 31% (95% CI: 20%-44%). The authors concluded that while grapefruit juice inhibits CYP1A2, the small in vivo effect suggests it generally should not cause clinically significant inhibition of other CYP1A2 drug substrates.
Fuhr U, Klittich K, Staib AH Br J Clin Pharmacol, 1993. PMID 8485024
1986 / Randomized controlled trial
Ten subjects with normal renal function took single doses of aluminium-containing antacids (1, 4, or 8 tablets containing 244 mg aluminium per tablet) with water, orange juice, or citric acid solution. Serum aluminium increased markedly when antacids were taken with citric acid (P < 0.001) or orange juice (P < 0.05), whereas taking them with water produced only a slight increase with 4 tablets. A significant increase in 24-hour urinary aluminium excretion followed all antacid doses. Estimated aluminium absorption was 8 and 50 times higher when antacids were taken with orange juice or citric acid, respectively, compared to water.
Weberg R, Berstad A Eur J Clin Invest, 1986. PMID 3100311
1986 / Experimental intervention trial
Ten healthy men ingested citric acid (as lemon juice), Al(OH)3, or Al(OH)3 plus citric acid twice daily between meals during 7-day periods. Mean whole blood aluminum concentrations increased from a pretreatment level of 5 (SD 3) micrograms/L to 9 (SD 4) micrograms/L after citric acid and 12 (SD 3) micrograms/L after Al(OH)3. Combined ingestion of Al(OH)3 and citric acid caused a more pronounced, highly significant increase to 23 (SD 2) micrograms Al/L (p < 0.001).
Slanina P, Frech W, Ekström LG, et al. Clin Chem, 1986. PMID 3948402
2011 / Retrospective observational study
A retrospective observational study examined adverse event complaints in a weight loss program (over 95% women) 3 months before and 3 months after switching multivitamin suppliers. Complaints of nausea and vomiting increased from 2 (out of 88,252 patients) to 166 (out of 88,468 patients; P < 0.0001), rash increased from 0 to 9 (P < 0.02), and total complaints increased from 11 to 194 (P < 0.0001). The reformulated multivitamin contained added citrus bioflavonoids, which inhibit cytochrome P450 enzyme systems and decrease clearance of exogenous estrogens, suggesting a potential drug interaction in women taking oral contraceptives or hormone replacement therapy.
Shows an association, not proof of cause and effect.
Greenway F, Fujioka K, Yu Y Am J Ther, 2011. PMID 20458212
2001 / Case reports
Researchers described two patients who developed localized and disseminated bullous phototoxic skin reactions within 48 to 72 hours after exposure to bergamot aromatherapy oil and subsequent ultraviolet exposure. One patient had no direct contact with the oil but developed bullous skin lesions following exposure to aerosolized oil in a sauna and subsequent UVA radiation in a tanning salon. The report highlights the potential health risks linked to the use of psoralen-containing aromatherapy oils.
Shows an association, not proof of cause and effect.
Kaddu S, Kerl H, Wolf P J Am Acad Dermatol, 2001. PMID 11511848
2000 / Case report
An 8-year-old child with familial Mediterranean fever developed signs of colchicine intoxication while taking prophylactic doses of the medication. The patient experienced gastrointestinal, central nervous system, cardiovascular, and haematological disturbances. The authors report that the child had been drinking high doses of natural grapefruit juice over 2 months, which combined with long-term colchicine therapy and a viral upper respiratory tract infection increased susceptibility to the drug.
Shows an association, not proof of cause and effect.
Goldbart A, Press J, Sofer S, et al. Eur J Pediatr, 2000. PMID 11131346
2010 / Review
This review evaluates metabolic and cardiovascular perspectives related to grapefruit consumption. Grapefruit or grapefruit juice consumption is associated with drug interactions—some fatal—mediated by intestinal CYP3A4, P-glycoprotein, and organic cation transporter proteins. Concurrently, grapefruit's rich flavonoid content has emerged as beneficial in managing degenerative conditions like diabetes and cardiovascular disorders, though the clinical extent of its drug interactions remains not fully determined.
Owira PM, Ojewole JA Cardiovasc J Afr, 2010. PMID 20972517
2006 / Narrative review
This review discusses the management of grapefruit-drug interactions. Grapefruit affects the metabolism of medications that undergo extensive intestinal cytochrome P450 3A4 metabolism, have low bioavailability, or possess a narrow therapeutic index, such as statins, antiarrhythmic agents, immunosuppressants, and calcium channel blockers. Management strategies include substituting equally effective alternative drugs that do not interact with grapefruit or excluding grapefruit from the diet and opting for other fruits, including other types of citrus.
Stump AL, Mayo T, Blum A Am Fam Physician, 2006. PMID 16939181